Actively Recruiting
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Led by Minneapolis Heart Institute Foundation · Updated on 2024-10-08
81
Participants Needed
1
Research Sites
330 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
CONDITIONS
Official Title
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with their first STEMI older than 18 years who had successful primary PCI and can give informed consent
- Mild or greater left ventricular dysfunction (LVEF less than 50%) on echocardiogram, cardiac MRI, or left ventriculogram after PCI
- Infarct size greater than 10% of left ventricular mass
- Presence of microvascular obstruction (MVO) greater than 10% of infarct size
You will not qualify if you...
- Contraindication to cardiac MRI
- Life expectancy less than 1 year
- Previous coronary artery bypass graft (CABG) or valve surgery
- Previous STEMI
- Pregnant, planning to become pregnant, or breastfeeding women
- Unresolved cardiogenic shock
- Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding premature ventricular contractions)
- Glomerular filtration rate less than 30 ml/min/1.73m2 or end-stage renal disease on dialysis
- Type 1 diabetes mellitus or history of diabetic ketoacidosis
- Type 1 or 2 diabetes with insulin use
- Prior intolerance to SGLT2 inhibitors
- Current use of SGLT2 inhibitors (for randomized patients)
- Contraindications to gadolinium contrast
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
Actively Recruiting
Research Team
S
Sarah Schwager, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here